Why ApoE4?

Brain amyloidosis can be determined accurately through measurement of Aβ concentration in the cerebrospinal fluid (CSF) or with imaging techniques (amyloid positron emission tomography (amyloid-PET)). However, these techniques are invasive and/or expensive and it is not possible to prescribe these tests to all patients. Additionally, they require specialized instrumentation and personnel and they are not available in all hospitals. There is an actual need of non-invasive and cost-effective test that can be easily implemented in the clinical practice for selection of patients to be subjected to CSF analysis or amyloid -PET for brain amyloidosis evaluation.

There are strong evidences that show that ApoE4 is closely related with brain amyloidosis. APOE ε4 carriers have twice as much probability of having a positive result on brain amyloidosis in the prodromal stage of the disease (mild cognitive impairment) ⁸ when compared to APOE ε4 non-carriers, and this probability increases up to 90-97% in the symptomatic phase of AD⁹. Therefore, ApoE4 is a reliable predictor of brain amyloidosis, especially in patients with symptoms of dementia.

e4Risk® is very reliable and cost-effective test that can detect APOE ε4 carriers with a blood sample and using the already available instrumentation of clinical laboratories and hospitals. These features make e4Risk® an optimal solution for detection of APOE ε4 carriers, and therefore of patients at high risk of brain amyloidosis, within the clinical practice. e4Risk® will provide a very relevant information that will help the clinician, along with the age and the results of other routine tests, to select patients for additional tests to confirm brain amyloidosis and help in the AD diagnosis process.

Likewise, a positive result in e4Risk® could help to determine the presence of brain amyloidosis in patients with mild cognitive impairment that are not candidates for additional tests for brain amyloidosis, since approximately 80% of APOE ε4 carriers older than 80 years with mild cognitive impairment have brain amyloidosis⁸.

The inclusion of e4Risk® in the initial routine test panel for cognitive impairment and dementia would accelerate the obtention of AD diagnosis and reduce the uncertainty time before diagnosis, since it would help clinicians to select specific confirmatory tests for the disease. In the mid-term, this test might be used in Primary care, where it could be incorporated into the clinical criteria for derivation of patients with subjective memory complaints to the specialist.

– Optimize AD diagnosis process by identification of patients with high risk of brain amyloidosis. ApoE4 is a reliable predictor of brain amyloidosis, especially of patients with dementia symptoms.

– Allow Enrichment of clinical trials with APOE ε4 carriers, a population of significant informative value from an epidemiological perspective. APOE ε4 is currently being used for patient stratification in the latest clinical trials evaluating experimental treatments for AD.

– Facilitate the adoption of preventive lifestyle-based interventions that could prevent or delay the development of the disease, and could in turn entail significant savings for healthcare systems. For example, it has been estimated that a 10% reduction in cardiovascular disease incidence would equate to a 10% saving in medical costs attributable to AD and related dementias¹⁵

-Enrichment of clinical trials with ApoE4 carriers, a population of significant informative value from an epidemiological perspective. This biomarker is currently being used for patient stratification in the latest clinical trials evaluating experimental treatments for AD ^1,2

-Administration of treatments during the earliest stages of the disease. Early identification of ApoE4 carriers would allow regular monitoring of this at-risk population and facilitate treatment administration once the first symptoms develop, thus maximizing neural tissue preservation.